The Technical Analyst
Kymera Therapeutics, Inc. [KYMR]
Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology
Kymera Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
7.16% $21.10
Last updated: 3 jul 2022 - 20:43
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 091.38 mill |
| EPS: | -2.49 |
| P/E: | 0.000 |
| Earnings Date: | Aug 04, 2022 |
| SharesOutstanding: | 51.72 mill |
| Avg Daily Volume: | 0.775 mill |
| RATING 2022-07-01 |
|---|
| B+ |
| Buy |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$23.87 (13.11%) $2.77 |
| Date: 2022-07-04 |
| True Range Average |
|---|
|
+/- $1.675 ( +/- 7.94%) Range: 19.43 - 22.78 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-06-29 | Ridloff Elena | Buy | 9 000 | Stock Option (Right to Buy) |
| 2022-06-15 | Bvf Partners L P/il | Buy | 12 000 | Stock Option (Right to Buy) |
| 2022-06-15 | Horobin Joanna | Buy | 12 000 | Stock Option (Right to Buy) |
| 2022-06-15 | Albers Jeffrey W. | Buy | 12 000 | Stock Option (Right to Buy) |
| 2022-06-15 | Booth Bruce | Buy | 12 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 59.50 |
| Last 100 transactions |
| Buy: 1 727 661 | Sell: 492 588 |
Forecast:
16:00 - $21.10
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $21.10
Forecast 2: 16:00 - $21.10
Forecast 3: 16:00 - $21.10
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $21.10 (7.16% ) |
| Volume | 0.583 mill |
| Avg. Vol. | 0.775 mill |
| % of Avg. Vol | 75.17 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KYMR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since 31-12-69
| Date | Signal | @ | Closed | % | Jun 29 - 16:20 | buy | $20.29 | N/A | Active |
|---|
KYMR
Latest Press Releases
2022-06-15 07:00:00 - Press Release
Kymera Therapeutics Doses First Patients In Phase 1 Oncology Trials Of Stat3 And Irakimid Degraders Kt-333 And Kt-413
Kt-333 is a first-in-class heterobifunctional degrader of the transcriptional regulator stat3 in development for t cell malignancies and solid tumors kt-413 is a first-in-class degrader of irak4 and the imid substrates ikaros and aiolos in development for myd88-mutant b cell lymphomas initial safety and proof-of-mechanism clinical data for both programs to be shared in second half of 2022 watertown, mass. , june 15, 2022 /prnewswire/ -- kymera therapeutics, inc. (nasdaq: kymr), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, has recently dosed the first patients in separate phase 1 clinical trials evaluating the stat3 degrader kt-333 and the irakimid degrader kt-413.
2022-05-20 07:30:00 - Press Release
Kymera Therapeutics Presented Preclinical Data Showcasing Impact Of Irak4 Degrader Kt-474 On Immune And Skin Cells At The Society For Investigative Dermatology Annual Meeting
Watertown, mass., may 20, 2022 (globe newswire) -- kymera therapeutics, inc. (nasdaq: kymr), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, presented data demonstrating that the clinical stage selective irak4 degrader kt-474 degrades irak4 and inhibits cytokine production in different immune and skin cell types at the society of investigative dermatology (sid) annual meeting 2022, taking place from may 18 - 21, 2022 in portland, oregon.
2022-05-05 08:00:00 - Press Release
Kymera Therapeutics To Share Novel Preclinical Findings Reinforcing The Advantage Of Irak4 Degraders Over Kinase Inhibitors As Well As First Stat3 Degrader Results In A Preclinical Model Of Th17 Inflammation
-data to be shared at the american association of immunologists (aai) annual meeting
2022-04-08 13:02:00 - Press Release
Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority Of Mdm2 Degradation Over Inhibition And Shares Profile Of Clinical Candidate Kt-253 At The American Association For Cancer Research (aacr) Annual Meeting 2022
Mdm2 degradation demonstrated differentiated biological activity and superior cell killing compared to small molecule inhibition in p53 wild-type tumors and led to tumor regressions in xenograft models of all and aml
2022-01-18 08:00:00 - Press Release
Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.d., To Board Of Directors
Watertown, mass., jan. 18, 2022 (globe newswire) -- kymera therapeutics, inc. (nasdaq: kymr), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of john maraganore, ph.d. to its board of directors. dr. maraganore joins kymera's board after having led alnylam pharmaceuticals as founding ceo and director and transformed the field of rna therapeutics for the last nearly 20 years.
Latest News
2022-06-01 07:00:00 - GlobeNewsWire
Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid Arthritis
WATERTOWN, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will present new preclinical data demonstrating that STAT3 degradation blocked Th17 development and cytokine release and prevented collagen-induced arthritis (CIA), a pre-clinical model of rheumatoid arthritis, today at the EULAR 2022 Congress in Copenhagen, Denmark.
2022-06-01 06:15:24 - InvestorPlace
3 Biotech Stocks to Buy Before They Boom
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. The post 3 Biotech Stocks to Buy Before They Boom appeared first on InvestorPlace.
2022-05-03 18:12:12 - Seeking Alpha
Kymera Therapeutics, Inc. (KYMR) CEO Nello Mainolfi on Q1 2022 Results - Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q1 2022 Results Conference Call May 3, 2022 8:00 AM ET Company Participants Nello Mainolfi - Founder and Chief Executive Officer Jared Gollob - Chief Medical Officer Bruce Jacobs - Chief Financial Officer Conference Call Participants Eliana Merle - UBS Brad Canino - Stifel Paul Jeng - Guggenheim Gospel Enyindah-Asonye - Morgan Stanley Kalpit Patel - B. Riley Divya Rao - Cowen and Company Eric Joseph - JPMorgan Zhiqiang Shu - Berenberg Operator Welcome to Kymera Therapeutics Quarterly Conference Call.
2022-05-03 14:21:02 - Benzinga
Why Kymera Therapeutics Shares Are Falling Today
In its Q1 earnings release, Kymera Therapeutics Inc (NASDAQ: KYMR) announced the selection of the equivalent of 100 mg, in the fed state, as the dose for the Phase 1 patient cohort (Part C). The cohort is expected to enroll up to 20 patients with hidradenitis suppurativa (HS) and atopic.
2022-05-03 13:09:42 - The Motley Fool
Why Kymera Therapeutics Stock Is Getting Hammered Today
2022-05-03 09:47:39 - Zacks Investment Research
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Lags Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.97% and 44.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-04-19 08:00:00 - GlobeNewsWire
Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences
Company to begin hosting quarterly calls to provide broad updates across pipeline Company to begin hosting quarterly calls to provide broad updates across pipeline
2022-03-02 07:00:00 - GlobeNewsWire
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
WATERTOWN, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in the following upcoming virtual investor conferences:
2022-02-24 11:35:32 - Zacks Investment Research
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Lags Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -83.33% and 27.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
2022-02-07 06:21:59 - Seeking Alpha
BMEZ: Buy Low, Hold For The Distribution And Rebound
